Sat, Apr 19, 2014, 11:56 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Regeneron Pharmaceuticals, Inc. Message Board

racavalli 116 posts  |  Last Activity: Apr 17, 2014 3:39 PM Member since: Jul 31, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Now Is the Perfect Time To Buy Cesca

    by screaminbuys Apr 15, 2014 8:20 PM
    racavalli racavalli Apr 17, 2014 3:39 PM Flag

    Shares are already sneaking back up and will be hitting record highs in the coming few months

    Sentiment: Strong Buy

  • Toxic wastewater tailings are the single biggest problem limiting BELLATRIX production and access to their reserves.

    The University of Alberta recently announced a breakthrough solution that will COST-EFFECTIVELY decontaminate toxic wastewater tailings from oil sands production and from fracking. Toxic wastewater enters the system and clean and safe water flows from the output.

    The University built a bench-lab model that validated the technology and performed exactly as predicted by purifying the wastewater with very little energy. Contaminants were dismantled and rendered perfectly safe using the AOS system.

    AOS will enable BELLATRIX to access a far greater amount of their reserves and will increase production significantly beyond today’s projections.

    BioLargo (BLGO) owns “AOS”.

    AOS is the key to abundant oil sands and fracking and will deliver what every oil producer is looking for . . . a cheap way to clean the ALL wastewater from fracking and oil sands recovery.


    The University is building a commercial sized pilot unit that is expected to be completed in 6 months

    The first pilot study will use an 8” pipe and can be scaled to ANY size pipe . . . 12 inch, 24 inch, 36 inch, 60 inch, 120 inch and bigger.

    Once news hits that the pilot study is successful AGAIN, BioLargo shares will advance to record highs because toxic wastewater is the single biggest problem in the trillion-dollar oil and gas industry today.

    BioLargo shares are only $.50 (fifty cents) today and can easily be one of the best performing stocks in your portfolio.

    BioLargo shares are tightly held and may be difficult to buy.

    Sentiment: Strong Buy

  • racavalli racavalli Apr 14, 2014 5:45 PM Flag

    It's true and I know a LOT OF INVESTORS WHO VERY RECENTLY GOT SCREWED BY CITICORP with Ampio shares at $7.00.

  • Reply to

    Please post link to Citibank Buy Recommendation

    by schausandy Apr 14, 2014 9:41 AM
    racavalli racavalli Apr 14, 2014 10:38 AM Flag

    Highly unlikely.

    CitiGroup is very large and when they institute overage with a target, shares ALWAYS respond immediately.

    Judging on Ampio's limping along, this strong;y suggests that no report has been issued.

    Sentiment: Strong Buy

  • Here's the NITRO!

    Multiple clinical trial results are so strong they are indicating that Stem Cell Therapy is going to be the new wave of medicine and based on actual trial results, the undisputed leader is:

    UNRIVALED AND PROVEN trial results demonstrate that Cesca Therapeutics (KOOL) is the most advanced Regenerative Medicine Stem Cell Therapeutics Company.

    These results are historical in any field of medicine.

    Cesca therapeutics recently announced record shattering clinical trial results from their 17 patient CLI trial:
    Highlights
    Before treatment, 100% of “No Option” patients required amputation
    12 months after treatment, 82.4% of patients had no amputation
    Pain level before treatment on a scale of 0 to 10 was SEVERE at 7.8
    Pain level 12 months after treatment was ALMOST NON-EXISTENT at 0.2
    6-minute walking distance before treatment was 14.5 meters
    6-minute walking distance 12 months after treatment was 157meters
    Before treatment, 11 patients had gangrene with or without ulceration
    12 months after treatment 0 patients had gangrene or ulceration
    NEW BLOOD VESSELS WERE REGENERATED AFTER TREATMENT.
    THERE WERE NO ADVERSE SIDE EFFECTS.
    MORE FACTS:

    CESCA’s AMI, Bone Union and Bone Marrow Stem Cell Transplant studies all show similar successes that are well advanced beyond peers

    CESCA shares are trading at less than $2.00 per share.

    If CESCA was trading at ONLY the AVERAGE MARKET CAP of their competitors, CESCA would be selling at $14.21 per share today.

    Sentiment: Strong Buy

  • Here's the NITRO!

    Multiple clinical trial results are so strong they are indicating that Stem Cell Therapy is going to be the new wave of medicine and based on actual trial results, the undisputed leader is:

    UNRIVALED AND PROVEN trial results demonstrate that Cesca Therapeutics (KOOL) is the most advanced Regenerative Medicine Stem Cell Therapeutics Company.

    These results are historical in any field of medicine.

    Cesca therapeutics recently announced record shattering clinical trial results from their 17 patient CLI trial:
    Highlights
    Before treatment, 100% of “No Option” patients required amputation
    12 months after treatment, 82.4% of patients had no amputation
    Pain level before treatment on a scale of 0 to 10 was SEVERE at 7.8
    Pain level 12 months after treatment was ALMOST NON-EXISTENT at 0.2
    6-minute walking distance before treatment was 14.5 meters
    6-minute walking distance 12 months after treatment was 157meters
    Before treatment, 11 patients had gangrene with or without ulceration
    12 months after treatment 0 patients had gangrene or ulceration
    NEW BLOOD VESSELS WERE REGENERATED AFTER TREATMENT.
    THERE WERE NO ADVERSE SIDE EFFECTS.
    MORE FACTS:

    CESCA’s AMI, Bone Union and Bone Marrow Stem Cell Transplant studies all show similar successes that are well advanced beyond peers

    CESCA shares are trading at less than $2.00 per share.

    If CESCA was trading at ONLY the AVERAGE MARKET CAP of their competitors, CESCA would be selling at $14.21 per share today.

    Sentiment: Strong Buy

  • Proven trial results demonstrate that Cesca Therapeutics is the most advanced Regenerative Medicine Stem Cell Therapeutics Company.

    These results are historical in any field of medicine.

    Cesca therapeutics (KOOL) recently announced record shattering clinical trial results from their 17 patient CLI trial:
    Highlights
    Before treatment, 100% of “No Option” patients required amputation
    12 months after treatment, 82.4% of patients had no amputation
    Pain level before treatment on a scale of 0 to 10 was SEVERE at 7.8
    Pain level 12 months after treatment was ALMOST NON-EXISTENT at 0.2
    6-minute walking distance before treatment was 14.5 meters
    6-minute walking distance 12 months after treatment was 157meters
    Before treatment, 11 patients had gangrene with or without ulceration
    12 months after treatment 0 patients had gangrene or ulceration
    NEW BLOOD VESSELS WERE REGENERATED AFTER TREATMENT.
    THERE WERE NO ADVERSE SIDE EFFECTS.
    MORE FACTS:

    CESCA’s AMI, Bone Union and Bone Marrow Stem Cell Transplant studies all show similar successes that are well advanced beyond peers

    CESCA shares are trading at less than $2.00 per share.

    If CESCA was trading at ONLY the AVERAGE MARKET CAP of their competitors, CESCA would be selling at $14.21 per share today.

    Sentiment: Strong Buy

  • Proven trial results demonstrate that Cesca Therapeutics is the most advanced Regenerative Medicine Stem Cell Therapeutics Company.

    These results are historical in any field of medicine.

    Cesca therapeutics (KOOL) recently announced record shattering clinical trial results from their 17 patient CLI trial:
    Highlights
    Before treatment, 100% of “No Option” patients required amputation
    12 months after treatment, 82.4% of patients had no amputation
    Pain level before treatment on a scale of 0 to 10 was SEVERE at 7.8
    Pain level 12 months after treatment was ALMOST NON-EXISTENT at 0.2
    6-minute walking distance before treatment was 14.5 meters
    6-minute walking distance 12 months after treatment was 157meters
    Before treatment, 11 patients had gangrene with or without ulceration
    12 months after treatment 0 patients had gangrene or ulceration
    NEW BLOOD VESSELS WERE REGENERATED AFTER TREATMENT.
    THERE WERE NO ADVERSE SIDE EFFECTS.
    MORE FACTS:

    CESCA’s AMI, Bone Union and Bone Marrow Stem Cell Transplant studies all show similar successes that are well advanced beyond peers

    CESCA shares are trading at less than $2.00 per share.

    If CESCA was trading at ONLY the AVERAGE MARKET CAP of their competitors, CESCA would be selling at $14.21 per share today.

    Sentiment: Strong Buy

  • racavalli racavalli Apr 12, 2014 12:09 PM Flag

    I know Macaluso, David and Vaughan and they are all as professional as anyone can ever be.

    Macaluso is particularly charismatic and very bright. He has excellent instincts and has been doing everything right.

    Ampio is fortunate to be blessed with this team that is about to make very big news.

    Those who stick it out with him and Ampio with find themselves in the Winners Circle!

    Sentiment: Strong Buy

  • Cost-effective Wastewater Solution Found - Huge Investment Opportunity
    Check out todays news, "The Future For Fracking".

    A small company named, BioLargo (BLGO) has a solution to the oil and gas industry's biggest problem for fracking and oil sands.

    Ant the solution has been validated by the University of Alberta.

    Biolargo's shares won't be cheap for long . . . and their AOS technology will be a boon to SLB and other major players.

    Sentiment: Strong Buy

  • Check out todays news, "The Future For Fracking".

    A small company named, BioLargo (BLGO) has a solution to the oil and gas industry's biggest problem for fracking and oil sands.

    Ant the solution has been validated by the University of Alberta.

    Biolargo's shares won;t be cheap for long . . . and their AOS technology will be a boon to Royal Dutch Shell and other major players.

    Sentiment: Strong Buy

  • racavalli racavalli Apr 10, 2014 1:11 AM Flag

    Cesca holding firm exactly as predicted and exactly as chart consolidation shows.

    Next move will be a sharp advance to $4.00.

    Sentiment: Strong Buy

  • Reply to

    shorts VERY nervous

    by shellerati48 Apr 9, 2014 10:21 AM
    racavalli racavalli Apr 9, 2014 3:05 PM Flag

    i don't think the shorts are nervous at all but they should be because the big spike is coming soon!

    Sentiment: Strong Buy

  • With 700 offices signed up, another 1,000 in legal about to close . . . and who knows how many more lining up to take advantage of Millennium's offer to provide patient's with free life-saving diagnostics and at the same time substantially increasing physician's income, Millennium is poised to become a large company in a huge industry and carry a very high price.

    Millennium is an exceptionally strong buy and long-term hold.

    Sentiment: Strong Buy

  • Reply to

    News today on 20 Week study

    by superforce_57 Apr 9, 2014 8:44 AM
    racavalli racavalli Apr 9, 2014 11:29 AM Flag

    the difference is that the presentation will not be by the company. it will be by Dr. Wei.

    this brings more credibility to Ampio

    Sentiment: Strong Buy

  • Reply to

    Citibank Buy Recommendation BOOM!!!!!

    by schausandy Apr 8, 2014 9:05 AM
    racavalli racavalli Apr 8, 2014 8:04 PM Flag

    So where is the recommendation?

    CitiGroup only had to wait ten days and it has been over a month and still NOTHING!

    Do you know something we don't

    Sentiment: Strong Buy

  • Reply to

    Something does feel right.

    by comes_with_babysitters Apr 3, 2014 11:24 PM
    racavalli racavalli Apr 8, 2014 1:57 PM Flag

    Agreed! It's always best to try to buy as low as possible. The only risk is that the stock might start moving away from your order, but you can always buy higher too.

    The key is to build a meaningful position and using averaging down or up to optimize your price because nobody can pick bottoms or tops.

    Sentiment: Strong Buy

  • Reply to

    Significant Events

    by ampereviewer Apr 7, 2014 11:45 PM
    racavalli racavalli Apr 8, 2014 12:16 PM Flag

    Well stated!

    In times like these, Ampio shareholders all need an occasional reminder of why they originally bought in.

    We give thanks to ampereviewer of such a reminder and for a solid vote of confidence.

    This is clearly a rare buying opportunity and the timing could not be better because we don't have to wait two or three years to see the fireworks.

    Ampio shares over exceptionally undervalued.

    Sentiment: Strong Buy

  • racavalli racavalli Apr 8, 2014 11:33 AM Flag

    It's always darkest before the dawn and KOOL is at the low end of its consolidation. NOBODY is expecting earnings to have any impact because the story is not about sales and earnings in this young company.

    The story clearly is about their unrivaled clinical trial results that have managed to leave their competitors in the dust.

    Bankers and analysts realize how undervalued Cesca is and are accumulating all they can buy at these giveaway prices.

    Remember, Cesca is no longer a device company . . . Cesca is a Stem Cell therapeutics company and they have produced the most exciting results in all of history.

    No sound argument can counter their accomplishment. No matter how their patients were selected (and they were carefully selected to demonstrate the power of their technology) nobody can argue that regrowing brand new blood vessels is not a major breakthrough in medicine.

    This technology will change medicine forever. And Cesca owns it!

    Sentiment: Strong Buy

  • AMPE has been sold and sold and sold and appears to be firming in the mid 5's.

    Investors know that a bullish report fro Jefferies and CitiGroup will be coming soon and some may be lining up to buy shares before the report comes out.

    There is also a freight train of news coming over the balance of this year that is expected to be substantial enough to rocket Ampio's shares to record highs.

    One result of the massive selling wave we have seen in growth stocks is that money is piling up on the sidelines and looking for the next opportunities.

    I believe AMPE is one of the new opportunities and that investors will soon be pouring money int Ampio shares.

    Sentiment: Strong Buy

REGN
296.74-3.40(-1.13%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.